TABLE 2.

Subgroup Regression Analyses for OS in [¹⁷⁷Lu]Lu-PSMA-617 Versus Docetaxel Arms

Variable	HR	95% CI	P
Age
<70 y (n = 24)	0.99	0.39–2.52	0.976
≥70 y (n = 16)	1.09	0.33–3.64	0.882
Gleason score
<8 (n = 14)	1.77	0.47–6.61	0.397
≥8 (n = 26)	0.70	0.28–1.78	0.454
Prior androgen-receptor pathway inhibitor
No (n = 14)	0.37	0.09–1.48	0.159
Yes (n = 26)	1.94	0.75–4.99	0.172
Extent of skeletal disease
<10 lesions (n = 8)	2.54	0.35–18.45	0.357
≥10 lesions (n = 32)	0.77	0.33–1.78	0.540
Visceral metastasis
No (n = 31)	0.86	0.36–2.08	0.744
Yes (n = 9)	2.47	0.57–10.69	0.226